Clinical Research Directory
Browse clinical research sites, groups, and studies.
Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors
Sponsor: Guangzhou Medical University
Summary
This is an open-label, single-arm, phase I/II trial of immune checkpoint inhibitor combined with pemetrexed intrathecal injection for leptomeningeal metastasis from solid tumors.
Official title: Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors: a Phase I/II Study
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
45
Start Date
2024-06-30
Completion Date
2026-07-31
Last Updated
2026-05-11
Healthy Volunteers
No
Conditions
Interventions
Toripalimab, pemetrexed
Drug 1: Toripalimab 40 mg; Drug 2: pemetrexed 15mg. intrathecal injection therapy
Locations (4)
The Affiliated Huizhou Hospital, Guangzhou Medical University
Huizhou, Guangdong, China
Huizhou First Hospital Affiliated to Guangdong Medical University
Huizhou, Guangdong, China
Beijing Chest Hospital, Capital Medical University
Beijing, China
Cancer Center, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine
Beijing, China